Equillium, Inc.

Equillium, Inc. is a biotechnology innovator focused on developing novel therapies for severe autoimmune and inflammatory disorders. The company's core business model revolves around the research, development, and potential commercialization of its product candidates, primarily EQ504 and EQ302. Revenue generation is currently derived from collaboration and license agreements, with no product sales to date. The company has incurred significant operating losses since its inception, with an accumulated deficit of $216.2 million as of December 31, 2025 ¹.

The company's pipeline includes two preclinical-stage product candidates. EQ504 is a novel aryl hydrocarbon receptor (AhR) modulator, which has demonstrated a therapeutically beneficial impact in multiple translational models by inducing anti-inflammatory cells and cytokines, reducing proinflammatory cells and cytokines, and improving intestinal tissue barrier function and repair. EQ504 is initially being developed for ulcerative colitis (UC) and other gastrointestinal (GI) diseases, with potential expansion into inflammatory lung diseases. The U.S. total addressable market for UC is estimated at approximately $12 billion by 2030 ². EQ302 is a first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21, formulated for oral delivery. This candidate is believed to be an effective treatment approach for certain GI indications, including celiac disease, an autoimmune disorder affecting approximately 2.3 million people in the United States ³. EQ302 has shown potency, stability, and permeability in the gut in preclinical and translational data.

For the fiscal year ended December 31, 2025, Equillium reported no revenue ⁴, a significant decrease from $41.095 million in revenue for the year ended December 31, 2024 ⁵. This prior year revenue was primarily from development funding ($28.3 million) and amortization of an upfront payment ($12.8 million) under an Asset Purchase Agreement with Ono Pharmaceutical Co., Ltd., which terminated on October 30, 2024 ⁶. The net loss for 2025 was $22.398 million ⁷, compared to a net loss of $8.067 million in 2024 ⁸. Basic and diluted EPS for 2025 was $(0.39) ⁹, compared to $(0.23) in 2024 ¹⁰.

Operating expenses totaled $23.634 million in 2025 ¹¹, down from $49.364 million in 2024 ¹². Research and development expenses decreased by $24.585 million, from $37.428 million in 2024 to $12.843 million in 2025 ¹³. This reduction was mainly due to the wind-down of clinical studies in 2025, including lower clinical development expenses, reduced CMC activities with Biocon, and lower consulting expenses related to the EQUATOR study. General and administrative expenses also decreased by $1.145 million, from $11.936 million in 2024 to $10.791 million in 2025 ¹⁴, primarily due to lower overhead costs such as franchise taxes, directors and officers insurance, and travel, as well as reduced legal expenses.

Cash and cash equivalents as of December 31, 2025, stood at $30.277 million ¹⁵, an increase from $18.085 million at December 31, 2024 ¹⁶. Net cash used in operating activities was $22.746 million in 2025 ¹⁷, compared to $19.026 million in 2024 ¹⁸. Net cash provided by financing activities was $30.427 million in 2025 ¹⁹, primarily from the sale of shares and pre-funded warrants in a private placement, which generated net proceeds of $27.9 million ²⁰. The company also received $1.8 million from the exercise of stock options ²¹ and approximately $0.7 million from the sale of shares under its 2023 ATM Facility ²².

Significant operational developments during the period include the termination of the collaboration and license agreement with Biocon Limited on September 30, 2025 ²³, which resulted in a $0.4 million reduction of research and development expense due to a set-off of amounts owed ²⁴. The Asset Purchase Agreement with Ono Pharmaceutical Co., Ltd. also automatically terminated on October 30, 2024, as Ono allowed its option to expire ²⁵. The company acquired exclusive worldwide rights to EQ504 through the acquisition of Ariagen, Inc. in October 2024 ²⁶, and exclusive worldwide rights to EQ302 and a proprietary platform through the acquisition of Bioniz Therapeutics, Inc. in February 2022 ²⁷.

Equillium's primary goal is to advance EQ504 into and through clinical development, with a Phase 1 proof-of-mechanism study for EQ504 planned to commence in mid-2026, and data expected approximately six months thereafter ²⁸. The company intends to initially develop EQ504 for ulcerative colitis and other GI diseases, with potential indication expansion opportunities for inflammatory lung diseases.

The company is also evaluating further advancement of EQ302, including product manufacturing and toxicology studies to support a potential Investigational New Drug (IND) filing and a first-in-human clinical study ²⁹. EQ302 is a preclinical-stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21, designed for oral delivery, and is considered a potential therapeutic option for GI diseases such as celiac disease.

Equillium expects its expenses to increase substantially in future periods due to the advancement of EQ504 into clinical development and potentially the resumption of EQ302 development ³⁰. The company anticipates incurring significant commercialization expenses for marketing, sales, manufacturing, and distribution if any product candidates obtain marketing approval, with some investments potentially made at-risk in advance of approval.

The company believes that its cash and cash equivalents of $30.3 million as of December 31, 2025 ³¹, combined with the gross proceeds of approximately $35.0 million from the March Private Placement ³², will be sufficient to fund its operations into 2029 ³³. However, this estimate is based on assumptions that may prove inaccurate, and additional funds may be needed sooner than anticipated.

Future capital requirements will depend on various factors, including the initiation, progress, timing, costs, and results of nonclinical and clinical studies for EQ504 and EQ302, the number and scope of indications pursued, regulatory review costs, manufacturing costs, drug formulation and device development costs, intellectual property protection expenses, operational system enhancements, personnel attraction and retention, public company costs, and the ability to secure partnerships or strategic transactions ³⁴. The company may also pursue additional capital through its 2023 ATM Facility, which allows for the sale of common stock with an aggregate offering price of up to $75.0 million ³⁵. As of the filing date, 1,719,485 shares have been sold under this facility ³⁶.

Equillium faces substantial risks, including significant losses since inception and the expectation of continued losses, with an accumulated deficit of $216.2 million as of December 31, 2025 ¹. The company will require substantial additional funding to complete development and commercialization of EQ504 and EQ302, and failure to raise this capital could force delays or elimination of research and development programs. Raising additional equity capital may cause dilution to stockholders, as evidenced by the issuance of 21,814,874 shares and pre-funded warrants for 30,816,705 shares in an August 2025 private placement ³⁷, and 1,179,508 shares and a pre-funded warrant for 17,698,593 shares in a March 2026 private placement ³⁸. The company is highly dependent on the successful development and regulatory approval of EQ504 and EQ302, and there is no guarantee of obtaining marketing approval or successful commercialization. Delays in clinical studies, which are expensive and time-consuming, could increase costs and delay revenue generation. Interim or preliminary clinical data may change, and the FDA may not accept data from non-U.S. clinical studies. The company has no marketing and sales organization and would need to invest significant resources or seek collaborators for commercialization. Competition from major pharmaceutical and biotechnology companies with greater resources and expertise is substantial. Unfavorable pricing regulations or third-party coverage and reimbursement policies could hinder profitability, especially given the impact of the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act of 2025, which are expected to reduce healthcare funding and access ³⁹. Reliance on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) introduces risks of production difficulties, supply chain disruptions, and non-compliance with regulatory requirements. Intellectual property protection is critical but uncertain, with risks of patent challenges, infringement claims, and the inability to obtain or enforce patents. The company is highly dependent on key personnel, and the loss of such individuals could adversely affect operations. Cybersecurity threats pose risks to information systems and data, potentially leading to regulatory investigations, litigation, and business disruptions. The company's ability to use net operating loss carryforwards may be limited by ownership changes. Furthermore, the company's announced cryptocurrency treasury strategy introduces significant volatility and liquidity risks, as well as legal, commercial, regulatory, and technical uncertainties, including potential reclassification of cryptocurrency as a security under the Investment Company Act of 1940 ⁴⁰.

Management's message to shareholders emphasizes the company's mission as a biotechnology innovator focused on developing life-changing therapeutics for severe autoimmune and inflammatory disorders. The primary strategic priority is to advance EQ504, a novel AhR modulator, into and through clinical development, with a Phase 1 proof-of-mechanism study planned for mid-2026 and data expected approximately six months thereafter ²⁸. Management also highlights the evaluation of further advancement for EQ302, including manufacturing and toxicology studies to support a potential IND filing and first-in-human clinical study. The company believes its cash and cash equivalents as of December 31, 2025, combined with the gross proceeds from the March Private Placement, will be sufficient to fund operations into 2029 ³³. This forward-looking statement is based on certain assumptions and estimates that may prove inaccurate. Management acknowledges the need for substantial additional funding to complete development and commercialization of its product candidates and plans to pursue additional capital through equity offerings, debt financings, and collaboration and license agreements.